American Research & Management Company’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $135K | Buy |
417
+9
| +2% | +$2.85K | 0.04% | 137 |
|
|
2022
Q2 | $132K | Buy |
408
+50
| +14% | +$15K | 0.03% | 146 |
|
|
2022
Q1 | $103K | Buy |
358
+75
| +27% | +$19.3K | 0.02% | 165 |
|
|
2021
Q4 | $78K | Buy |
283
+25
| +10% | +$6.34K | 0.02% | 181 |
|
|
2021
Q3 | $60K | Hold |
258
| – | – | 0.01% | 196 |
|
|
2021
Q2 | $59K | Hold |
258
| – | – | 0.01% | 206 |
|
|
2021
Q1 | $48K | Sell |
258
-318
| -55% | -$62.2K | 0.01% | 199 |
|
|
2020
Q4 | $97K | Buy |
576
+258
| +81% | +$38.5K | 0.03% | 162 |
|
|
2020
Q3 | $47K | Hold |
318
| – | – | 0.01% | 185 |
|
|
2020
Q2 | $52K | Buy |
318
+18
| +6% | +$2.76K | 0.02% | 182 |
|
|
2020
Q1 | $42K | Hold |
300
| – | – | 0.02% | 179 |
|
|
2019
Q4 | $39K | Hold |
300
| – | – | 0.01% | 201 |
|
|
2019
Q3 | $34K | Hold |
300
| – | – | 0.01% | 211 |
|
|
2019
Q2 | $33K | Sell |
300
-1,000
| -77% | -$118K | 0.01% | 229 |
|
|
2019
Q1 | $169K | Buy |
1,300
+1,000
| +333% | +$122K | 0.05% | 141 |
|
|
2018
Q4 | $35K | Hold |
300
| – | – | 0.01% | 195 |
|
|
2018
Q3 | $32K | Hold |
300
| – | – | 0.01% | 215 |
|
|
2018
Q2 | $26K | Hold |
300
| – | – | 0.01% | 205 |
|
|
2018
Q1 | $23K | Hold |
300
| – | – | 0.01% | 235 |
|
|
2017
Q4 | $25K | Hold |
300
| – | – | 0.01% | 241 |
|
|
2017
Q3 | $26K | Hold |
300
| – | – | 0.01% | 215 |
|
|
2017
Q2 | $25K | Hold |
300
| – | – | 0.01% | 210 |
|
|
2017
Q1 | $25K | Hold |
300
| – | – | 0.01% | 201 |
|
|
2016
Q4 | $22K | Sell |
300
-400
| -57% | -$29.8K | 0.01% | 224 |
|
|
2016
Q3 | $56K | Hold |
700
| – | – | 0.02% | 168 |
|
|
2016
Q2 | $55K | Sell |
700
-100
| -13% | -$7.53K | 0.02% | 159 |
|
|
2016
Q1 | $58K | Hold |
800
| – | – | 0.02% | 160 |
|
|
2015
Q4 | $67K | Sell |
800
-415
| -34% | -$34.4K | 0.03% | 154 |
|
|
2015
Q3 | $102K | Hold |
1,215
| – | – | 0.04% | 128 |
|
|
2015
Q2 | $101K | Hold |
1,215
| – | – | 0.04% | 134 |
|
|
2015
Q1 | $88K | Hold |
1,215
| – | – | 0.04% | 139 |
|
|
2014
Q4 | $84K | Hold |
1,215
| – | – | 0.03% | 142 |
|
|
2014
Q3 | $79K | Hold |
1,215
| – | – | 0.03% | 148 |
|
|
2014
Q2 | $76K | Sell |
1,215
-100
| -8% | -$5.97K | 0.03% | 151 |
|
|
2014
Q1 | $77K | Hold |
1,315
| – | – | 0.03% | 147 |
|
|
2013
Q4 | $67K | Buy |
1,315
+65
| +5% | +$3.25K | 0.02% | 155 |
|
|
2013
Q3 | $63K | Hold |
1,250
| – | – | 0.03% | 155 |
|
|
2013
Q2 | $61K | Buy |
+1,250
| New | +$68K | 0.02% | 158 |
|
Other funds holding LLY
American Research & Management Company's LLY Position: Q3 2022 in Review
American Research & Management Company increased its Eli Lilly (LLY) stake by 2.2% in Q3 2022, buying an estimated $2.85K and bringing the position to 417 shares worth $135K. The position accounts for 0.04% of the portfolio, ranked #137.
American Research & Management Company first reported a position in LLY in Q2 2013 and has held it in 38 quarters since. The position peaked at $169K in Q1 2019. 2,485 funds tracked by Wall St. Rank hold LLY as of Q3 2022.
- American Research & Management Company held 417 shares of Eli Lilly worth $135K as of Q3 2022.
- American Research & Management Company bought 9 Eli Lilly shares in Q3 2022, an estimated $2.85K.
- Eli Lilly made up 0.04% of American Research & Management Company's portfolio in Q3 2022, its #137 holding.
- American Research & Management Company first reported a position in Eli Lilly in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Eli Lilly position peaked at $169K in Q1 2019.
- 2,485 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.